Market capitalization | €708.52m |
Enterprise Value | €709.82m |
P/E (TTM) P/E ratio | 37.09 |
EV/FCF (TTM) EV/FCF | 36.57 |
EV/Sales (TTM) EV/Sales | 6.96 |
P/S ratio (TTM) P/S ratio | 6.95 |
P/B ratio (TTM) P/B ratio | 7.00 |
Dividend yield | 1.41% |
Last dividend (FY23) | €0.38 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a Revenio Group forecast:
7 Analysts have issued a Revenio Group forecast:
Sep '24 |
+/-
%
|
||
Revenue | 102 102 |
6%
6%
|
|
Gross Profit | 45 45 |
0%
0%
|
|
EBITDA | 31 31 |
1%
1%
|
EBIT (Operating Income) EBIT | 25 25 |
4%
4%
|
Net Profit | 19 19 |
9%
9%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Revenio Group Oyj engages in ophthalmic diagnostics and the manufacture and sale of ophthalmic devices. The firm's ophthalmic diagnostic solutions include intraocular pressure measurement devices under the iCare brand, retinal imaging devices, and perimeters. The company was founded in 2001 and is headquartered in Vantaa, Finland.
Head office | Finland |
CEO | Jouni Toijala |
Employees | 216 |
Founded | 2001 |
Website | www.reveniogroup.fi |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.